Company intelligence
CellCentric
Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.
About CellCentric
Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.
Verified activity
Signals from CellCentric
8 published signals
People
CellCentric welcomed Paolo Pucci as Non-Executive Director and Jason Cavalier as Chief Financial Officer to the Board.
Reported by CellCentric
People
CellCentric welcomed Paolo and Jason on board.
Reported by Will West
People
CellCentric hired Paolo Pucci and Jason Cavalier as new team members.
Reported by Will West
Products & Services
CellCentric is bringing Inobrodib to market.
Reported by Elizabeth Jeanne Thatcher
Research & Knowledge
CellCentric published research from over 150 physicians confirming a growing market and need for new treatments in the multiple myeloma space.
Reported by CellCentric
Research & Knowledge
CellCentric completed extensive market research with US multiple myeloma doctors to view the evolving treatment landscape, the need and opportunities for novel mechanism of action, oral drug approaches, and after and instead of bispecifics.
Reported by Will West
People
CellCentric hired Haripriya Shankar to join the field medical team to support multiple myeloma in the West.
Reported by Haripriya Shankar, Ph.D.
Research & Knowledge
CellCentric is progressing its investigational all oral triplet InoPd to treat multiple myeloma, with potential after and instead of bispecific therapies based on latest market research.
Reported by Will West